Cellectar Biosciences Inc (NASDAQ:CLRB)
| 1.25 Delayed Data As of Sep 18 |  +0.03 / +2.46%Today’s Change | 1.01 Today|||52-Week Range 3.33 | -44.44% Year-to-Date |
Latest CLRB News | Press Releases
| Cellectar Biosciences Phase 2 Data In Multiple Myeloma Is Worth A Look Sep 14 / Seeking Alpha - Paid Partner Content | Cellectar's lead asset shows 40% ORR in heavily pre-treated MM patients in mid-stage study Sep 09 / Seeking Alpha - Paid Partner Content |
| Intra-Cellular Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma Sep 12 / Seeking Alpha - Paid Partner Content | Cellectar's lead asset shows 40% response rate in multiple myeloma study Sep 09 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 1.22 |
| Today’s open | 1.20 |
| Day’s range | 1.20 - 1.29 |
| Volume | 26,519 |
| Average volume (3 months) | 1,013,489 |
| Market cap | $32.5M |
Data as of 3:54pm ET, 09/18/2020
Growth & Valuation
| Earnings growth (last year) | +64.87% |
| Earnings growth (this year) | +48.01% |
| Earnings growth (next 5 years) | +1.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 1.45 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NBYNovaBay Pharmaceutic... | +0.01 | +1.82% |
| NEOSNeos Therapeutics In... | +0.03 | +4.54% |
| HOTHHoth Therapeutics In... | -0.05 | -2.07% |
| MLNDMillendo Therapeutic... | -0.01 | -0.61% |
Data as of 3:59pm ET, 09/18/2020
Financials
| Next reporting date | November 17, 2020 |
| EPS forecast (this quarter) | -$0.20 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$14.1M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Florham Park, New Jersey |
Forecasts
